Ardelyx (ARDX) vs Collegium Pharmaceutical (COLL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ardelyx (ARDX) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 44.8% versus a loss of 45.2%. Over five years, ARDX leads with a +234.8% price change compared with +37.7% for COLL. Collegium Pharmaceutical is the larger company by market cap ($768.2 million vs $751.6 million), about 1.0 times the size.
On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.5x vs 18.9x for Ardelyx). Collegium Pharmaceutical converts more of its revenue into profit, with a net margin of 8.1% versus -15.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | COLL |
|---|---|---|
| Share price | $2.99 | $24.72 |
| Market cap | $751.60M | $768.18M |
| 1-day change | -2.29% | -1.94% |
| YTD return | -48.71% | -46.61% |
| 1-year return | -44.83% | -45.24% |
| 5-year return | +234.83% | +37.72% |
| P/E ratio (TTM) | — | 22.68 |
| Forward P/E | 18.92 | 3.49 |
| EPS (TTM) | $-0.23 | $1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $407.32M | $780.57M |
| Revenue growth (YoY) | +22.09% | +23.62% |
| Net income (latest FY) | $-61.60M | $62.87M |
| Gross margin | 90.29% | 59.35% |
| Operating margin | -10.06% | 23.01% |
| Net margin | -15.12% | 8.05% |
| 52-week high | $8.40 | $50.79 |
| 52-week low | $2.80 | $21.43 |
| Distance from 52-week high | -64.40% | -51.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +318.06% | +77.99% |
| Average volume | 4.46M | 754.45K |
| Shares outstanding | 251.37M | 31.08M |
| Employees | 489 | 423 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Collegium Pharmaceutical is more profitable, keeping 8.1 cents of every revenue dollar as net income versus -15.1 cents for Ardelyx.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
ARDX vs COLL FAQ
Which is bigger, Ardelyx or Collegium Pharmaceutical?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $768.18M compared with $751.60M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or COLL?
ARDX returned -44.83% over the past 12 months, compared with -45.24% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Collegium Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.